Last reviewed · How we verify
Sevoflurane - Neostigmine 70
This is a combination of sevoflurane (a volatile anesthetic) and neostigmine (a cholinesterase inhibitor) used to maintain anesthesia and reverse neuromuscular blockade.
This is a combination of sevoflurane (a volatile anesthetic) and neostigmine (a cholinesterase inhibitor) used to maintain anesthesia and reverse neuromuscular blockade. Used for General anesthesia maintenance during surgical procedures, Reversal of neuromuscular blockade post-operatively.
At a glance
| Generic name | Sevoflurane - Neostigmine 70 |
|---|---|
| Also known as | Inhalational anesthesia |
| Sponsor | Pontificia Universidade Catolica de Sao Paulo |
| Drug class | Volatile anesthetic with cholinesterase inhibitor |
| Target | GABA receptors (sevoflurane); acetylcholinesterase (neostigmine) |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | FDA-approved |
Mechanism of action
Sevoflurane is a volatile anesthetic agent that depresses the central nervous system to produce unconsciousness and analgesia during surgery. Neostigmine is an acetylcholinesterase inhibitor that prevents the breakdown of acetylcholine, thereby enhancing neuromuscular transmission and reversing the effects of non-depolarizing neuromuscular blocking agents used during anesthesia.
Approved indications
- General anesthesia maintenance during surgical procedures
- Reversal of neuromuscular blockade post-operatively
Common side effects
- Postoperative nausea and vomiting
- Emergence agitation
- Hepatotoxicity (rare)
- Malignant hyperthermia (rare)
- Cholinergic effects from neostigmine (salivation, bronchospasm)
Key clinical trials
- Laryngeal Mask Airway Facilitates a Safe and Smooth Emergence From Anesthesia in Patients Undergoing Craniotomy (NA)
- Consistency Evaluation of the qCON, qNOX Indices and Bispectral Index (NA)
- Three Different Doses of Neostigmine on the Reversal of Cisatracurium-induced Moderate Neuromuscular Blockade (PHASE4)
- Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: